Flag of the European Union EU Clinical Trials Register Help

Clinical trials for NEUROFIBROMATOSIS

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43628   clinical trials with a EudraCT protocol, of which   7211   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):428-32. Epub 2006 Jan 11. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, Buchert R, Clausen M, Mautner VF.
    Active substance: FLUDEOXYGLUCOSE
    Study summary document link (including results):
    View full study record
    Document reference: 28091
    Study title: WIDEMANN B. Novel Drugs for Children With Cancer /Neurofibromatosis. 2001. Crisp Data Base National Institutes of Health. 2003. WIDEMANN B. Novel Drugs for Children With Cancer /Neurofibromatosis. 2001. Crisp Data Base National Institutes of Health. 2003.
    Active substance: RALTITREXED
    Study summary document link (including results):
    View full study record
    Document reference: 35267
    Study title: MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis; Chateil JF; Br. J. Radiol.; 2001 vol.74 p.24-31MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis; Chateil JF; Br. J. Radiol.; 2001 vol.74 p.24-31
    Active substance: GADOTERIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28859
    Study title: Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, et al.. Epub 2006 Jan 11. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. [brenner-2006]Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):428-32. Brenner W 2006
    Active substance: Steripet
    Study summary document link (including results): 2011-09 GE response Template List of published articles.doc
    View full study record
    Document reference: 48635
    Study title: Clin Nucl Med. 1999 Jun;24(6):435-9. Tc-99m DTPA used as reference imaging to evaluate the distribution of other tumor-seeking tracers in tumors associated with neurofibromatosis. Suga K, Hirabayashi A, Kishimoto K, Kume N, Matsumoto T, Matsunaga N. Clin Nucl Med. 1999 Jun;24(6):435-9. Tc-99m DTPA used as reference imaging to evaluate the distribution of other tumor-seeking tracers in tumors associated with neurofibromatosis. Suga K, Hirabayashi A, Kishimoto K, Kume N, Matsumoto T, Matsunaga N.
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44556
    Study title: Kloos RT, Rufini V, Gross MD, Shapiro B. Bone scans in neurofibromatosis: neurofibroma, plexiform neuroma and neurofibrosarcoma. J Nucl Med. 1996 Nov;37(11):1778-83. Kloos RT, Rufini V, Gross MD, Shapiro B. Bone scans in neurofibromatosis: neurofibroma, plexiform neuroma and neurofibrosarcoma. J Nucl Med. 1996 Nov;37(11):1778-83.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43558
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA